Chung Kenneth Jordan Ng Cheong, Wilkinson Chris, Veerasamy Murugapathy, Kunadian Vijay
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University Newcastle upon Tyne, UK.
Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundations Trust Newcastle upon Tyne, UK.
Interv Cardiol. 2021 Mar 31;16:e05. doi: 10.15420/icr.2020.18. eCollection 2021 Apr.
The world's population is ageing, resulting in more people with frailty receiving treatment for cardiovascular disease (CVD). The emergence of novel interventions, such as transcatheter aortic valve implantation, has also increased the proportion of older patients being treated in later stages of life. This increasing population burden makes the assessment of frailty of utmost importance, especially in patients with CVD. Despite a growing body of evidence on the association between frailty and CVD, there is no consensus on the optimal frailty assessment tool for use in clinical settings. Previous studies have shown limited concordance between validated frailty instruments. This review evaluates the evidence on the utility of frailty assessment tools in patients with CVD, and the effect of frailty on different outcomes measured.
全球人口正在老龄化，导致更多身体虚弱的人接受心血管疾病（CVD）治疗。经导管主动脉瓣植入等新型干预措施的出现，也增加了老年患者在生命后期接受治疗的比例。这种不断增加的人口负担使得虚弱评估变得至关重要，尤其是在CVD患者中。尽管关于虚弱与CVD之间关联的证据越来越多，但对于临床环境中使用的最佳虚弱评估工具尚无共识。先前的研究表明，经过验证的虚弱评估工具之间的一致性有限。本综述评估了虚弱评估工具在CVD患者中的效用证据，以及虚弱对所测量的不同结局的影响。
